CRPC w/ Bone Metastases - Results from #40

Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer May 31, 2017

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer. May 3, 2017

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 May 1, 2017

Doped silica fibre thermoluminescence measurements of radiation dose in the use of (223)Ra April 28, 2017

Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel April 25, 2017

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT April 7, 2017

Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models April 2, 2017

The Role of Therapeutic Layering in Optimizing Treatment for Patients with Castration-Resistant Prostate Cancer (RADAR II) March 27, 2017

Impact of locally advanced or metastatic prostate cancer on the quality of life March 7, 2017

Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multi center database- Abstract March 7, 2017

Survival prognosis and variable selection: A case study for metastatic castrate resistant prostate cancer patients January 25, 2017

The current status of prophylactic femoral intramedullary nailing for metastatic cancer January 25, 2017

[Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases] January 11, 2017

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial December 13, 2016

Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223 December 5, 2016

SEOM Clinical Guideline for bone metastases from solid tumours (2016) December 1, 2016

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold November 25, 2016

Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology November 24, 2016

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data November 22, 2016

Radium-223 Therapy of Bone Metastases in Prostate Cancer November 15, 2016

Page 3 of 11